



BMA BIOMEDICALS


Polyclonal Antibody to Human Complement C3a

Chicken Anti Human Complement C3adesArg (67-76)

The complement system is part of the innate immune system representing humoral defence. Activation of the complement cascade *via* the classical, the alternative or the Lectin pathway liberates several biologically active by-products, among them the anaphylatoxin C3a. Measurement of C3a (and C4a) in plasma or other body fluids can yield important clues about the pathological, and particularly also the inflammatory status of an organism. In serum, C3a activity is under strict control of the carboxypeptidase N. This enzyme rapidly cleaves the C-terminal arginine, thereby generating C3adesArg which shows greatly reduced biological activity as compared to C3a. Thus, the biological activity of C3a is focused mainly on its point of generation, while the degradation product C3adesArg remains relatively stable until it is cleared from the circulation. The antibody was generated against the carboxy-terminal neoepitope which is not exposed on C3, allowing discrimination between C3 and C3a.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Product Number:	T-1520 (Lot 02AP0802)
Clone:	Polyclonal antibody
Host species, isotype:	Chicken IgY
Quantity:	100µg
Format:	Affinity purified, liquid Supplied as 0.1ml solution. This stock solution contains 1mg/ml IgY, phosphate buffered saline pH 7.2 (PBS) and 0.1% sodium azide as a preservative.
Stability:	Original vial: 6 months at 4° - 8°C from date of purchase.
Applications:	Tested for ELISA. This antibody was found not to cross-react with human C4a. The titer with native human C3a was 1:5000. Please see www.bma.ch for protocols and general information.
Immunogen:	Peptide coupled to carrier protein
Protein database:	<u>human-Q16581</u>



For in vitro research only. This product contains sodium azide as a preservative.